Axsome Therapeutics Settles Patent Litigation on SUNOSI

Axsome Therapeutics ( (AXSM) ) has shared an update.

On May 27, 2025, Axsome Therapeutics announced a settlement agreement with Hetero Labs Ltd. to resolve patent litigation regarding Axsome’s product SUNOSI (solriamfetol). The agreement allows Hetero to sell a generic version of SUNOSI in the U.S. starting in 2040, contingent on FDA approval and other conditions. This settlement is subject to review by U.S. regulatory authorities, and similar litigation with other parties remains pending.

The most recent analyst rating on (AXSM) stock is a Buy with a $175.00 price target. To see the full list of analyst forecasts on Axsome Therapeutics stock, see the AXSM Stock Forecast page.

Spark’s Take on AXSM Stock

According to Spark, TipRanks’ AI Analyst, AXSM is a Neutral.

Axsome Therapeutics’ stock is moderately rated, driven by strong revenue growth and positive corporate events, offset by financial instability and negative valuation metrics. The positive earnings call highlights future potential, yet consistent profitability and regulatory challenges remain key risks.

To see Spark’s full report on AXSM stock, click here.

More about Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company focused on treating central nervous system disorders. It develops differentiated products with novel mechanisms of action, offering FDA-approved treatments for conditions such as major depressive disorder, excessive daytime sleepiness, and migraine, with multiple late-stage development programs addressing various neurological and psychiatric conditions.

Average Trading Volume: 711,311

Technical Sentiment Signal: Buy

Current Market Cap: $5.17B

See more insights into AXSM stock on TipRanks’ Stock Analysis page.